Pluristem Carving Out Distinct Niche in Orthopedic Medicine With New Clinical Trials in Rotator Cuff RepairMay 8, 2013 7:03 am | by The Associated Press | Comments
Pluristem (NASDAQ: PSTI) recently announced a new Phase I trial to check safety and evaluate effectiveness of its PLX-PAD cells in chronic tendonitis often leading to rotator cuff disorders, common in tennis players and golfers, where there are roughly 200,000 rotator cuff surgeries done each...
Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United StatesMay 8, 2013 7:00 am | by The Associated Press | Comments
SUNNYVALE, Calif--(BUSINESS WIRE)--May 8, 2013--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration (FDA) to initiate patient enrollment...
Demand for Hybrid Solutions to Spur European Interventional Radiology and Cardiology Markets, finds Frost & SullivanMay 8, 2013 4:00 am | by PR Newswire | Comments
LONDON, May 8, 2013 /PRNewswire/ -- The European market for interventional radiology and cardiology is heading towards maturity, especially in Western Europe. Although the economic slowdown and fewer orders had a negative impact on revenues in 2012, it is expected that expanding...
Meeting Announcement: June 13, 2013 Microbiology Devices Panel of the Medical Devices Advisory CommitteeMay 8, 2013 12:00 am | by U.S. Food & Drug Administration | Comments
The committee's discussion will involve making recommendations regarding regulatory classification to either confirm class I or reclassify these devices into class II with special controls. The committee will address issues such as device performance and public health impact to determine whether special controls are needed to ensure the safety and effectiveness of these tests through their total product life cycle.
Dr. Eisuke Fukuma has treated 58 breast cancer patients with cryoablation over the last 6 years under a research protocol at Kameda Medical Center in Japan. As of today, none of the patients have had a tumor reoccur or distant metastases. By this non-surgical treatment, Dr. Fukuma's patients avoid the risks and potential cosmetic impact of major breast cancer surgery.
The Combat Ready Clamp made history Friday when it received new critical indications from the FDA making it the first device of its kind approved to treat unmanageable amputations and pelvic wounds not addressable with standard limb tourniquets.
Adults with depression and who receive certain types of anti-depressants have an increased risk of developing Clostridium difficile, a costly and serious hospital-associated infection, according to a new University of Michigan Health System study.
Mitek Sports Medicine, a leading orthopaedics sports medicine company, announced the launch of the HEALIX 3.4-mm Suture Anchor, the company's smallest dual-thread suture anchor for rotator cuff repair, and the launch of a new double-loaded minimally invasive partial thickness rotator cuff repair system, as part of its HEALIX TRANSTEND Implant System.
Maxim Surgical, a new designer and manufacturer of spinal implants, has received 510(k) clearance from the FDA for its new MaxFuse-C cervical interbody fusion system made of Zeniva polyetheretherketone rods from Solvay Specialty Polymers.
GHX has announced Case Xpert and Order Intelligence, the healthcare industry’s first end-to-end supply chain solutions for managing and tracking implantable medical devices, including the physician preference items (PPI) used in operating rooms.
Duke University biomedical engineers have grown three-dimensional human heart muscle that acts just like natural tissue. This advancement could be important in treating heart attack patients or in serving as a platform for testing new heart disease medicines.
LAKE OSWEGO, Ore.--(BUSINESS WIRE)--May 7, 2013--BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced that the Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator...
Vast Majority of Americans Would Want to Know if They Have a Serious Illness or Injury, Even If There Is No Cure, New Survey ShowsMay 7, 2013 9:14 am | by The Associated Press | Comments
MALVERN, Pa.--(BUSINESS WIRE)--May 7, 2013--Amidst ongoing national debate about healthcare costs, new research unveiled today by Siemens Healthcare shows that the vast majority of Americans (92 percent) agree that “the value of knowing exactly what is wrong with their health is as important as...
Enrollment Completed for Low-Risk Aortic and Mitral Patient Groups For On-X® Prosthetic Heart Valve Anticoagulation Clinical StudyMay 7, 2013 9:00 am | by The Associated Press | Comments
MINNEAPOLIS--(BUSINESS WIRE)--May 7, 2013--On-X ® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the Low-Risk Aortic Valve and Mitral Valve Patient Groups has been completed. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was initiated with US FDA...
Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman’s breast cancer risk, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.